These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 29624625)

  • 1. Clinical management of seronegative and seropositive rheumatoid arthritis: A comparative study.
    Choi S; Lee KH
    PLoS One; 2018; 13(4):e0195550. PubMed ID: 29624625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differing X-ray patterns in seronegative and seropositive rheumatoid arthritis.
    Gadeholt O; Hausotter K; Eberle H; Klink T; Pfeil A
    Clin Rheumatol; 2019 Sep; 38(9):2403-2410. PubMed ID: 31123977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria.
    Nordberg LB; Lillegraven S; Lie E; Aga AB; Olsen IC; Hammer HB; Uhlig T; Jonsson MK; van der Heijde D; Kvien TK; Haavardsholm EA;
    Ann Rheum Dis; 2017 Feb; 76(2):341-345. PubMed ID: 27094444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.
    Shu J; Bykerk VP; Boire G; Haraoui B; Hitchon C; Thorne JC; Tin D; Keystone EC; Pope JE;
    J Rheumatol; 2015 Nov; 42(11):2023-8. PubMed ID: 26329342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy.
    Jonsson MK; Hensvold AH; Hansson M; Aga AB; Sexton J; Mathsson-Alm L; Cornillet M; Serre G; Lillegraven S; Fevang BS; Catrina AI; Haavardsholm EA
    Arthritis Res Ther; 2018 Jul; 20(1):146. PubMed ID: 30001740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis.
    Katchamart W; Koolvisoot A; Aromdee E; Chiowchanwesawakit P; Muengchan C
    Rheumatol Int; 2015 Oct; 35(10):1693-9. PubMed ID: 25903353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR/EULAR classification of rheumatoid arthritis.
    Van Hoovels L; Jacobs J; Vander Cruyssen B; Van den Bremt S; Verschueren P; Bossuyt X
    Ann Rheum Dis; 2018 May; 77(5):667-677. PubMed ID: 29363510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions.
    Castrejón I; Dougados M; Combe B; Fautrel B; Guillemin F; Pincus T
    J Rheumatol; 2016 Jul; 43(7):1285-91. PubMed ID: 27084913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rheumatoid Arthritis and Risk of Parkinson Disease in Korea.
    Kang J; Eun Y; Jang W; Cho MH; Han K; Jung J; Kim Y; Kim GT; Shin DW; Kim H
    JAMA Neurol; 2023 Jun; 80(6):634-641. PubMed ID: 37126341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort.
    Mouterde G; Rincheval N; Lukas C; Daien C; Saraux A; Dieudé P; Morel J; Combe B
    Arthritis Res Ther; 2019 Jun; 21(1):140. PubMed ID: 31171038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
    Bird P; Hall S; Nash P; Connell CA; Kwok K; Witcombe D; Thirunavukkarasu K
    RMD Open; 2019; 5(1):e000742. PubMed ID: 30886732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity.
    Arntz OJ; Pieters BCH; Thurlings RM; Wenink MH; van Lent PLEM; Koenders MI; van den Hoogen FHJ; van der Kraan PM; van de Loo FAJ
    Front Immunol; 2018; 9():2388. PubMed ID: 30420853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of anti-cyclic citrullinated peptide antibodies with clinical and radiological disease severity in rheumatoid arthritis.
    Gupta A; Kaushik R; Kaushik RM; Saini M; Kakkar R
    Curr Rheumatol Rev; 2014; 10(2):136-43. PubMed ID: 25599684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.
    Rannio T; Asikainen J; Kokko A; Hannonen P; Sokka T
    J Rheumatol; 2016 Apr; 43(4):699-706. PubMed ID: 26879355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement.
    Wechalekar MD; Lester S; Proudman SM; Cleland LG; Whittle SL; Rischmueller M; Hill CL
    Arthritis Rheum; 2012 May; 64(5):1316-22. PubMed ID: 22135142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seasonal distribution of relapse onset in rheumatoid arthritis and spondyloarthropathy: the possible effect of the solar factor.
    Rozin A; Balbir-Gurman A; Schapira D
    Clin Exp Rheumatol; 2003; 21(2):161-9. PubMed ID: 12747269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticollagen type II antibodies are associated with an acute onset rheumatoid arthritis phenotype and prognosticate lower degree of inflammation during 5 years follow-up.
    Manivel VA; Mullazehi M; Padyukov L; Westerlind H; Klareskog L; Alfredsson L; Saevarsdottir S; Rönnelid J
    Ann Rheum Dis; 2017 Sep; 76(9):1529-1536. PubMed ID: 28336519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis.
    Barra L; Pope JE; Orav JE; Boire G; Haraoui B; Hitchon C; Keystone EC; Thorne JC; Tin D; Bykerk VP;
    J Rheumatol; 2014 Dec; 41(12):2361-9. PubMed ID: 25274884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies against cyclic citrullinated peptide don't decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis.
    Kolarz B; Majdan M; Dryglewska M; Darmochwal-Kolarz D
    Rheumatol Int; 2011 Nov; 31(11):1439-43. PubMed ID: 20473501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
    Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
    Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.